Showing results (91-100 of 131) with videos related to
Sort By:
Pageof 14
Investigational New Drugs|November 1, 2016
Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-oldFrederic Bigot, Pascaline Boudou-Rouquette, Jennifer Arrondeau, et al.Clinical Therapeutics|April 21, 2019
Pharmacokinetics and Pharmacodynamics of Once-daily Prolonged-release Tacrolimus in Liver Transplant RecipientsMarie Allard, Alicja Puszkiel, Filomena Conti, et al.Journal of Pharmaceutical and Biomedical Analysis|March 7, 2017
Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patientsAlicja Puszkiel, Gaëlle Noé, Pascaline Boudou-Rouquette, et al.European Journal of Clinical Pharmacology|March 23, 2023
Predictive factors associated with pemetrexed acute toxicityMathilde Bonnet, Anne Jouinot, Pascaline Boudou-Rouquette, et al.Oncotarget|September 3, 2016
Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinibGaёlle Noé, Audrey Bellesoeur, Audrey Thomas-Schoemann, et al.Cancers|June 5, 2019
Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with NivolumabGaëlle Noé, Audrey Bellesoeur, Lisa Golmard, et al.Arthritis & Rheumatology (Hoboken, N.J.)|May 3, 2023
Association Between Plasma Rituximab Concentration and the Risk of Major Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitides During Rituximab Maintenance TherapyNihel Khoudour, Florence Delestre, Fabienne Jabot-Hanin, et al.Expert Opinion on Drug Safety|April 4, 2014
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patientsOlivier Huillard, Emilie Boissier, Benoit Blanchet, et al.Frontiers in Pharmacology|October 18, 2021
A Cyclic Peptide Epitope of an Under-Explored VEGF-B Loop 1 Demonstrated In Vivo Anti-Angiogenic and Anti-Tumor ActivitiesLei Wang, Meng Xu, Haofeng Hu, et al.Expert Opinion on Investigational Drugs|January 21, 2015
Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeuticsJennifer Arrondeau, Olivier Huillard, Camille Tlemsani, et al.Pageof 14